Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...